An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers

This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts.

Start Date14 Jun 2017

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with SC-004(Stemcentrx)

100 Translational Medicine associated with SC-004(Stemcentrx)

100 Patents (Medical) associated with SC-004(Stemcentrx)

Literatures (Medical) associated with SC-004(Stemcentrx)

01 Jan 2001·ChemotherapyQ4 · MEDICINE

In vitro and in vivo Antibacterial Activity and Pharmacokinetics of SC-002 and Its Derivative, SC-004: New Oral Cephalosporins

Q4 · MEDICINE

Article

Author: Numata, K. ; Fujita, M. ; Yamamoto, R. ; Kondo, K. ; Saito, H. ; Matsuyama, M. ; Hanada, K. ; Akashi, T. ; Sugita, K. ; Hiyama, T. ; Nozawa, M. ; Nagate, T. ; Kaneda, Y. ; Onodera, A. ; Kobori, T.

SC-002 is a novel oral cephalosporin possessing a unique thiadiazolylethenyl moiety at the 3 position. In the present study, it was the most active against gram-positive bacteria among oral cephalosporins such as cefdinir (CFDN), cefpodoxime, cefditoren and cefaclor (CCL). It was equal to or 16 times more active than CFDN against standard and clinical strains. In particular, against clinical isolates of Morganella morganii and Haemophilus influenzae, SC-002 was 8–64 times more active than CFDN. The antibacterial activity of SC-002 against some β-lactam-resistant strains was superior to that of CFDN. The in vivo antibacterial activity of SC-004, a pivaloyloxymethyl ester of SC-002, was 1.2–8 times more protective against systemic infections due to Streptococcus pneumoniae, Escherichia coli and Klebsiella pneumoniae than that of CFDN. The therapeutic effects of SC-004 on experimental respiratory tract infections caused by S. pneumoniae or H. influenzae were superior to those of CFDN and CCL. SC-004 showed higher and longer-lasting blood levels and higher urinary excretion in pharmacokinetics in mice.

100 Deals associated with SC-004(Stemcentrx)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrial Carcinoma	Phase 1	United States	AbbVie, Inc.	14 Jun 2017
Fallopian Tube Carcinoma	Phase 1	United States	AbbVie, Inc.	14 Jun 2017
Ovarian Epithelial Carcinoma	Phase 1	United States	AbbVie, Inc.	14 Jun 2017
Peritoneal Neoplasms	Phase 1	United States	AbbVie, Inc.	14 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis